Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy-Reference-Cited by-同舟云学术

Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy

Published:2022-06-16 Issue:5 Volume:149 Page:1755-1763
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Bodor J. Nicholas^ORCID,Bauman Jessica R.,Handorf Elizabeth A.,Ross Eric A.,Clapper Margie L.,Treat Joseph

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04089-9.pdf

Reference30 articles.

1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643

2. Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G et al (2017) Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 12(5):563–569. https://doi.org/10.1007/s11523-017-0510-9

3. Dong ZY, Zhang JT, Liu SY, Su J, Zhang C, Xie Z et al (2017a) EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 6(11):e1356145. https://doi.org/10.1080/2162402X.2017.1356145

4. Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY et al (2017b) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23(12):3012–3024. https://doi.org/10.1158/1078-0432.CCR-16-2554

5. Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A et al (2018) BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol 13(8):1128–1137. https://doi.org/10.1016/j.jtho.2018.04.024

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study;International Immunopharmacology;2024-06

2. Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort;Clinical Lung Cancer;2024-05

3. The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations;Translational Cancer Research;2024-01

4. The Predictive Value of Inflammatory Markers, Prealbumin, and Albumin in the Clinical Efficacy of PD-1 Therapy in Advanced Solid Tumor Patients;Advances in Clinical Medicine;2024

5. Perioperative Immunotherapy in Non-Small Cell Lung Cancer;Current Treatment Options in Oncology;2023-12